Event
8 - 10 Nov.

Financial Times Global Pharmaceutical & Biotechnology Conference

Sustaining innovation and collaboration beyond the pandemic

Monday, 10:00 a.m.  GMT

This industry-led conference brought together the world’s biggest pharma companies and other major organizations across the life sciences and health care value chain. The annual event was essential to stay up to date with the innovation and growth across areas such as drug discovery, clinical trials and market access, and exploring new frontiers for business and growth.

Register to access recordings*

 

While the life sciences and health care industry is witnessing a rise of environmental and societal impact, how focused are investors in this regard? At the same time, the role of companies in tackling the pandemic is more important than ever. While technological innovation is constantly disrupting the pharma landscape, how will it reshape manufacturing and supply chains for uninterrupted operations in the new normal? The industry has also been embracing patient-centered approaches in its strive to improve consumer empowerment. But, does patient centricity make strategic sense? Deloitte leaders, along with industry peers, unpacked many of these critical questions at the FT Global Pharmaceutical & Biotechnology Conference 2021, which brought together the biggest life sciences and health care leaders from across the globe virtually to discuss. The leaders navigated the route to deliver better health care outcomes in an uncertain world.

Deloitte was once again the lead sponsor of the 2021 Financial Times Global Pharmaceutical & Biotechnology Conference and was pleased to offer a free complimentary registration to this year’s conference.

Register to access recordings*

Conference themes:

  • Innovating and collaborating: Assess the legacy of COVID-19 for healthcare and life sciences and the potential impact on how products are developed in the future
  • Investing and expanding: Explore the pharma biotech investment landscape and identify opportunities for growth around the world
  • Engaging and empowering: Gain global insights on market access and the future of healthcare from different stakeholders including pharma, payers, patients and regulators

 

Deloitte participation sessions:

In this session, the industry and government leaders discussed how can healthcare sector companies build on their role in tackling the pandemic to attract socially responsible investors to focus on ESG.

Panelists:

  • Daniella Foster, Global VP and Head of Public Affairs, Science and Sustainability, Consumer Health, Bayer
  • Nazneen Rahman, Founder and CEO, YewMaker

Moderated by - James Gregson, Life Sciences & Healthcare industry leader, Deloitte UK

Recommended reading:

COP26 – Our hopes for a healthier, collaborative, interconnected future

The ESG agenda can help life sciences companies sustain momentum

In this session, the panel members discussed about the shift in balance of power between pharma, payers, patients and other stakeholders shift in the next few years. They also discussed on how new drugs should be brought to market.

Panelists:

  • Carole Longson, Life Sciences Advisor, Centre for Health Technology Evaluation, NICE
  • Margo Warren, Head of Policy, Access to Medicines Foundation
  • Sanjay Gupta, Vice President and Head of Global Real-World Experience (RWE) and US Health Economics & Outcomes Research (HEOR), Oncology Business Group, Eisai

Moderated by - Hanno Ronte, Life Sciences & Healthcare industry leader, Deloitte Monitor

Recommended reading:

Access and Affordability Programmes | Reducing inequalities in access to medicines

Deloitte Market Access Excellence (MAx) commercial framework

This session discussed about how business models are affected by making patient centricity more of a priority and the leaders and industry experts also decoded the meaning for the balance of power between pharma and the patient.

Panelists:

  • Alicia Staley, Vice President, Patient Engagement, Medidata
  • Betül Susamis Unaran, Chief Strategy and Digital Officer, Zur Rose Group
  • Gilles Marrache, SVP, Regional General Manager, Europe, Latin America, Middle East, Africa and Canada, Amgen
  • Freda Lewis-Hall, Former Chief Patient Officer, Pfizer

Moderated by - Vicky Levy, Global Life Sciences Sector Leader, Deloitte

Recommended reading:

Is pharma ready to focus on the consumer?

Striving to become more patient-centric in life sciences

Global governance toolkit for digital mental health

In this session, leaders discussed the lessons pandemic taught us about how to support vaccine development and access in an emergency. They also mapped the commercial landscape for vaccines evolving and what can we expect to see in terms of innovation.

Panelists:

  • Judy Stewart, Senior Vice President, Head of US Vaccines, GlaxoSmithKline
  • Lovisa Afzelius, Origination Partner, Flagship Pioneering
  • Nell Beattie, Chief Business Officer, VBI Vaccines
  • Rasmus Bech Hansen, Co-founder and CEO, Airfinity

Moderated by - Greg Reh, Global Life Sciences & Health Care Industry Leader, Deloitte

Recommended reading:

Securing trust in the global COVID-19 supply chain

In this session, the panelists discussed about the vast scope for innovation with much investment going into the development of off-the-shelf allogeneic therapies. They also looked at the market trends for cell and gene therapies and prospects for allogeneic therapies for conditions other than cancer.

Panelists:

  • Matthew Durdy, CEO, Cell and Gene Therapy, Catapult
  • Dick Sundh, Vice President, Head of Australia, Canada and Europe, Kite, a Gilead Company
  • Jo Brewer, SVP Allogeneic Research, Adaptimmune
  • Richard Scott, Chief Medical Officer, Genomics England

Moderated by - Hussain Mooraj, Next Gen Therapy Practice Lead, Principal, Deloitte Consulting LLP

Recommended reading:

Cell and gene therapy

In this session, the industry leaders discussed about the scope of digital innovation and other measures which the pharma and biotech companies can adopt to make their manufacturing and supply chain operations more efficient and resilient.

Panelists:

  • Angela Bowden, Partner, Deloitte UK
  • Linzell Harris, SVP Global Supply Chain and Strategy, AstraZeneca
  • Shabbir Dahod, President and CEO, TraceLink

Recommended reading:

Intelligent drug supply chain

*Registration required to access conference recordings. Complimentary registration is available for senior executives in the life sciences and health care industry only and is subject to final approval by the Financial Times Live.

8 - 10 Nov. 2021 10:00 a.m. GMT